R
Rakesh K. Jain
Researcher at Harvard University
Publications - 1528
Citations - 198912
Rakesh K. Jain is an academic researcher from Harvard University. The author has contributed to research in topics: Angiogenesis & Cancer. The author has an hindex of 200, co-authored 1467 publications receiving 177727 citations. Previous affiliations of Rakesh K. Jain include Government Medical College, Thiruvananthapuram & University of Oslo.
Papers
More filters
Journal ArticleDOI
Increased rates of CD4+ and CD8+ T lymphocyte turnover in simian immunodeficiency virus-infected macaques
Michael Rosenzweig,MaryAnn DeMaria,D. Harper,Stuart W. Friedrich,Rakesh K. Jain,R. Paul Johnson +5 more
TL;DR: This work used the nucleoside analogue bromodeoxyuridine (BrdUrd) in combination with five-color flow cytometric analysis to evaluate T lymphocyte turnover rates in normal and simian immunodeficiency virus (SIV)-infected rhesus macaques, providing direct evidence for increased rates of both CD4(+) and CD8(+) T cell turnover in AIDS virus infection.
Journal ArticleDOI
A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder
TL;DR: 5 mg vortioxetine did not differ significantly from placebo in reducing depression symptoms after 6 wk of treatment in adults with MDD in an out-patient setting.
Journal ArticleDOI
Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages.
Joao Incio,Priya Suboj,Priya Suboj,Shan M. Chin,Trupti Vardam-Kaur,Hao Liu,Tai Hato,Tai Hato,Suboj Babykutty,Suboj Babykutty,Ivy X. Chen,Vikram Deshpande,Rakesh K. Jain,Dai Fukumura +13 more
TL;DR: The alleviation of desmoplasia by metformin was associated with a reduction in ECM remodeling, epithelial-to-mesenchymal transition (EMT) and ultimately systemic metastasis in overweight diabetic PDAC patients.
Journal ArticleDOI
A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapy
TL;DR: Model simulations of various antiangiogenic strategies show that those therapies that effectively target both endothelial and endothelial progenitor cells, either by restoring the balance between angiogenic stimulators and inhibitors or by targeting both types of cells directly, are most effective at delaying tumor growth.
Journal ArticleDOI
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer
Rebecca S. Heist,Dan G. Duda,Dushyant V. Sahani,Marek Ancukiewicz,Panos Fidias,Lecia V. Sequist,Jennifer S. Temel,Alice T. Shaw,Nathan A. Pennell,Joel W. Neal,Leena Gandhi,Thomas J. Lynch,Jeffrey A. Engelman,Rakesh K. Jain +13 more
TL;DR: The imaging biomarker studies indicate that bevacizumab-based treatment—while reducing blood flow, volume, and permeability in the overall population—may be associated with improved survival in patients with improved tumor vasculature and blood perfusion after treatment.